Author:
Husseiny Ebtehal M.,Abulkhair Hamada S.,Saleh Asmaa,Altwaijry Najla,Zidan Riham A.,Abdulrahman Fatma G.
Subject
Organic Chemistry,Drug Discovery,Molecular Biology,Biochemistry
Reference62 articles.
1. Potential of cyclin-dependent kinase inhibitors as cancer therapy;Abdel-Magid;ACS Med. Chem. Lett.,2021
2. E.M. Husseiny, H. S. Abulkhair, N.M. El-Dydamony, K.E. Anwer, Exploring the cytotoxic effect and CDK-9 inhibition potential of novel sulfaguanidine-based azopyrazolidine-3,5-diones and 3,5-diaminoazopyrazoles, Bioorg. Chem. (2023) 106397. doi: 10.1016/j.bioorg.2023.106397.
3. The anticancer and EGFR-TK / CDK-9 dual inhibitory potentials of new synthetic pyranopyrazole and pyrazolone derivatives : X-ray crystallography, in vitro, and in silico mechanistic investigations;Musa;J. Biomol. Struct. Dyn.,2023
4. National Cancer Institute, FDA Approves Ribociclib, Expands Palbociclib Approval for Metastatic Breast Cancer, (2017). https://www.cancer.gov/news-events/cancer-currents-blog/2017/fda-ribociclib-palbociclib-breast-cancer (accessed November 20, 2022).
5. Real-world patient characteristics, utilization patterns, and outcomes of US patients with HR+, HER2− metastatic breast cancer treated with abemaciclib;Smyth;Drugs - Real World Outcomes.,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献